Navigation Links
Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Date:6/1/2009

SEATTLE and ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today the presentation of encouraging Phase 1 safety and efficacy results following administration of low doses of TRU-016 in heavily pre-treated patients with high-risk genomic factors and relapsed or refractory chronic lymphocytic leukemia (CLL). TRU-016 is the Company's proprietary anti-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)) product candidate.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

Abstract 3017: A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)), in Relapsed and Refractory CLL -- Early Promising Clinical Activity

The clinical data presented at the American Society of Clinical Oncology (ASCO) are preliminary results from an ongoing Phase 1 / 2 clinical trial (#16007) of TRU-016 for the treatment of CLL and small lymphocytic leukemia (SLL). The objectives of the Phase 1 TRU-016 CLL study were to define safety and tolerability, identify a maximum tolerated dose, evaluate pharmacology and pharmacodynamics, and assess preliminary clinical activity. Patients received either one dose weekly for four weeks, or three doses the first week followed by three additional weekly doses. Patients were also able to receive up to two additional cycles if clinical benefit was observed.

At the time of the presentation, data were available for 26 patients enrolled in the Phase 1 dose escalation trial, all of whom had received an average of 6.5 prior treatments, including at least one fludarabine-containing regimen. All patients had also previously received rituximab or other anti-CD20 therapies an average of three times, either as a single agent
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
4. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
5. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
6. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
7. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
8. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
9. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015  Research ... addition of the "An Introduction to the ... 2015)" conference to their offering. ... the European medical device legislation. It will explain ... involvement of Notified Bodies, how to choose one ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has ... Legislation (London, UK - November 16-17, 2015)" conference ... EU modules concerning Pharmacovigilance are a major departure in ... Europe . The intention of the course ... examine how they overlap and fit together and what ...
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... Companies" to their offering. This ... clinical specialty, aimed at improving patient care by ... adjust the dose of drugs for improving outcome. ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2
... , , HOUSTON, Nov. 16 Cyberonics, Inc. ... to its tax position. , In its fiscal second quarter ... GAAP tax benefit of approximately $40 million resulting from the ... losses. The recognition of this tax benefit follows from ...
... , , LOS ANGELES, Nov. ... a 40-year-old Indian rhinoceros, has successfully completed treatment for ... to deliver electronic, x-ray based therapy directly to cancer ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20091116/SF11909 ) , Randa was ...
Cached Medicine Technology:Cyberonics Provides Update on Tax Position 2Cyberonics Provides Update on Tax Position 3Cyberonics Provides Update on Tax Position 4L.A. Zoo Announces Successful Cancer Treatment of Rhinoceros With Electronic Brachytherapy 2L.A. Zoo Announces Successful Cancer Treatment of Rhinoceros With Electronic Brachytherapy 3
(Date:9/3/2015)... ... September 03, 2015 , ... Global Vision , the world leader ... spotlighting its award-winning print and artwork inspection solutions, ScanProof and ArtProof at ... at the Olympia London, booth #F33 , Be the first to get a sneak ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... speakers for its upcoming virtual conference, “Proven Pharmacy Benefit Strategies for a Rapidly ... as CVS Health, Express Scripts and Milliman, will discuss how plan sponsors are ...
(Date:9/3/2015)... , ... September 03, 2015 , ... Hunters Creek ... Survivor Foundation with a champion AKC Black Lab Puppy. Celebrate Fall 2015 with unlimited ... for friends and family to enjoy Thanksgiving and Christmas with an extra big smile. ...
(Date:9/3/2015)... ... 2015 , ... ProScrub is a set of automated tools that allow Final ... speed effects without the use of keyframes. Utilize ProScrub's powerful sliders to determine ... perfect complements to energetic video productions. ProScrub is a Final Cut Pro ...
(Date:9/3/2015)... ... ... an unavoidable result of incision or injury to the skin. Unsightly as it may be, ... of a scar is dependent on many factors – the size and depth of the ... near invisibility on their own over a period of months,” says Dr. Jocelyn Lieb ...
Breaking Medicine News(10 mins):Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4
... , WEDNESDAY, Sept. 21 (HealthDay News) -- How ... they see a pediatrician, dermatologist or internist, a new ... birth to age 18 are affected by psoriasis, a ... flaky, dry skin. Researchers from University of California, ...
... 21, 2011) A soy germ-based nutritional supplement containing ... skin wrinkles of the outer corner of the eyes ... S-equol have potential to slow skin aging, according to ... in the peer-review journal Menopause and presented ...
... America (ASA) will include more than 1,000 presentations in the ... speech; the science of music; the impact of noise on ... irritating impacts the way we learn, work, and play. ... place October 31 - November 4 in San Diego, California, ...
... (HealthDay News) -- Most of the 220,000 people who undergo ... follow-up procedures they could have to remove any loose skin ... surgeons. However, not all patients who undergo so-called ... dramatic weight loss, said one doctor who,s an obesity expert. ...
... whose work is advancing understanding of neurodegenerative diseases, has ... highest honors bestowed on an individual in the United ... of neurology in the UCSF Memory and Aging Center, ... dementia, a family of neurological syndromes usually afflicting ...
... can invade your bloodstream, break into your brain and ... contagious protozoa infect more than half the world,s population, ... Cornell researchers recently discovered how T. gondii ... it the first known parasite to control its host,s ...
Cached Medicine News:Health News:Kids With Psoriasis Get Inconsistent Care 2Health News:Soy-based natural S-equol supplements improve crow's feet skin wrinkles in menopausal women 2Health News:Soy-based natural S-equol supplements improve crow's feet skin wrinkles in menopausal women 3Health News:Acoustical Society meeting: Highlights and media registration 2Health News:Acoustical Society meeting: Highlights and media registration 3Health News:Acoustical Society meeting: Highlights and media registration 4Health News:Acoustical Society meeting: Highlights and media registration 5Health News:Acoustical Society meeting: Highlights and media registration 6Health News:Many Unaware of Plastic Surgery Options After Weight Loss Procedures 2Health News:UCSF neurologist William Seeley, M.D., named MacArthur Fellow 2Health News:UCSF neurologist William Seeley, M.D., named MacArthur Fellow 3Health News:UCSF neurologist William Seeley, M.D., named MacArthur Fellow 4Health News:Researchers discover how 'promiscuous parasites' hijack host immune cells 2Health News:Researchers discover how 'promiscuous parasites' hijack host immune cells 3
... A new Transnasal Lacrimal Stent has been ... B. Becker, M.D., the Transnasal Lacrimal Stent addressed ... and other forms of endoscopic DCR. Brought in ... relatively large diameter. Because there is no need ...
...
... electrophysiology system is the Espion. This is an ... wide variety of stimulators for different types of ... ,The Espion system was designed from the ... standard clinical visual function tests, ERG, VEP, PERG, ...
... SIREMOBIL Iso-C3D is based on SIREMOBIL ... the industry. In the intra-operative 3D-Mode, the ... the motorized 190 orbital movement. This allows ... in greater precision during the procedure. This ...
Medicine Products: